Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists

Current Oncology

Pedro A. I. A. Silva¹  Moisés S. M. Lopes¹  Taciana Mutão¹  Denis S. Shimba¹  Cheng T. Yen¹  Angel A. T. Uchiyama¹  Eliza D. Ricardo¹  Larissa M. Machado¹  Jefferson R. Pimenta¹  Renata D. Peixoto² 

[1] Centro Especializado em Oncologia, Hospital Alemão Oswaldo Cruz, São Paulo 01327-001, Brazil;Centro Paulista de Oncologia, Grupo Oncoclínicas, São Paulo 04538-132, Brazil;

关键词: proton pump inhibitors;    chemotherapy;    immunotherapy;    drug-drug interaction;    tyrosine kinase inhibitors;   

DOI  :  10.3390/curroncol28010076

来源: DOAJ

【 摘 要 】

Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide, including among cancer patients. However, drug-drug interactions between PPIs and other agents may lead to decreased drug absorption with possible reduced therapeutic benefit, or even increased toxicity. Unfortunately, only scarce data exist regarding the safety of concomitant PPI use with anti-cancer agents. We aim at reviewing current evidence on this possible interaction by dividing anti-cancer agents by class. Until further data is available, we encourage healthcare providers to limit unnecessary PPI overuse.

【 授权许可】

Unknown